Sativex has been developed,
produced and marketed by
GW Pharmaceuticals

World leaders
Image
icons

GW Pharmaceuticals
has established a world-
leading position in
cannabinoid science
and medicine

Our mission

To unlock the potential of the cannabis plant through rigorous scientific investigations and extensive clinical trials to improve the lives of seriously ill patients

Our achievements

The drive to find solutions for complex medical problems has led us to gain regulatory approval of world-first cannabis-based medicines1–3

Our future

GW Pharmaceuticals is committed to leveraging our experience, expertise and extensive body of research in cannabinoid science to treat other diseases where significant unmet need exists

 

References:
1. FDA. FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy.www.fda.gov/news-events/pressannouncements/fda-approves-first-drugcomprised-active-ingredient-derived-marijuanatreat-rare-severe-forms (accessed February 2021).
2. EMA. Epidyolex. www.ema.europa.eu/en/medicines/human/EPAR/epidyolex (accessed February 2021).
3. Patented Medicine Prices Review Board. Annual report 2006. http://www.pmprbcepmb.gc.ca/view.asp?ccid=905 (accessed February 2021).

 

 

Fulfilling unmet needs
Image
test img

Our products are designed to
help seriously ill patients with
clear unmet needs, such as
those with MS spasticity

Despite a range of available treatment options, many patients and healthcare professionals are dissatisfied with their current spasticity treatment4,5

Image
graph
Image
graph-mobile

Learn about the burden MS spasticity places on patients

 

MS, multiple sclerosis.

 

References:
1. NICE. CG186. November 2019.
2. Flachenecker P et al. Acta Neurol Scand 2014; 129: 154–162.

 

 

 

MS, multiple sclerosis.

 

References:
1. FDA. FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy. www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms (accessed February 2021).
2. EMA. Epidyolex. www.ema.europa.eu/en/medicines/human/EPAR/epidyolex (accessed February 2021).
3. Patented Medicine Prices Review Board. Annual report 2006. http://www.pmprb-cepmb.gc.ca/view.asp?ccid=905 (accessed February 2021).
4. NICE. CG186. November 2019.
5. Flachenecker P et al. Acta Neurol Scand 2014; 129: 154–162.